Multiple Myeloma Clinical Trials in Atlanta
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
J
Recruiting
- Multiple Myeloma
- JNJ-68284528
- +4 more
- San Francisco, California
- +43 more
2022-03-28
Mar 28, 2022N
Completed
- Chronic Myelogenous Leukemia
- +9 more
- Fludarabine
- +3 more
- Atlanta, GeorgiaNorthside Hospital
2022-04-04
Apr 4, 2022G
N
Completed
- Multiple Myeloma
- Atlanta, GeorgiaBlood and Marrow Transplant Group of Georgia
2022-04-04
Apr 4, 2022T
Active, not recruiting
- Multiple Myeloma
- Placebo
- Ixazomib
- Fountain Valley, California
- +277 more
2022-03-23
Mar 23, 2022G
Active, not recruiting
- Multiple Myeloma
- Belantamab mafodotin frozen liquid
- Belantamab mafodotin lyophilized powder
- New Haven, Connecticut
- +58 more
2022-03-21
Mar 21, 2022P
Active, not recruiting
- Multiple Myeloma
- Lenalidomide
- +3 more
- Birmingham, Alabama
- +45 more
2022-03-29
Mar 29, 2022J
J
Active, not recruiting
- Multiple Myeloma
- Daratumumab
- +11 more
- Duarte, California
- +21 more
2022-03-24
Mar 24, 2022J
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Active, not recruiting
- Multiple Myeloma
- Little Rock, Arkansas
- +56 more
2022-03-24
Mar 24, 2022J
Active, not recruiting
- Multiple Myeloma
- Daratumumab
- +2 more
- Birmingham, Alabama
- +106 more
2022-03-24
Mar 24, 2022J
Active, not recruiting
- Multiple Myeloma
- Daratumumab IV
- +3 more
- Birmingham, Alabama
- +211 more
2022-03-24
Mar 24, 2022J
Recruiting
- Multiple Myeloma
- Birmingham, Alabama
- +81 more
2022-03-24
Mar 24, 2022J
C
Active, not recruiting
- Multiple Myeloma
- bb2121 carfilzomib
- +3 more
- Scottsdale, Arizona
- +18 more
2022-03-23
Mar 23, 2022J
Active, not recruiting
- Multiple Myeloma
- Lenalidomide
- +3 more
- Birmingham, Alabama
- +35 more
2022-03-24
Mar 24, 2022J
Active, not recruiting
- Multiple Myeloma
- Daratumumab Subcutaneous (SC) Administration
- Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
- Atlanta, Georgia
- +11 more
2022-03-24
Mar 24, 2022J
J
Active, not recruiting
- Multiple Myeloma
- Daratumumab
- +2 more
- Little Rock, Arkansas
- +145 more
2022-03-24
Mar 24, 2022G
Recruiting
- Multiple Myeloma
- Belantamab mafodotin
- +5 more
- Atlanta, Georgia
- +41 more
2022-03-23
Mar 23, 2022R
Recruiting
- Multiple Myeloma
- Miami, Florida
- +21 more
2022-03-22
Mar 22, 2022N
G
Active, not recruiting
- Multiple Myeloma
- Belantamab mafodotin
- +3 more
- Birmingham, Alabama
- +31 more
2022-03-21
Mar 21, 2022B
No longer available
- Multiple Myeloma
- Elotuzumab in combination with Lenalidomide and Dexamethasone
- Concord, California
- +26 more
2022-03-17
Mar 17, 2022G
Recruiting
- Multiple Myeloma
- Belantamab mafodotin
- San Francisco, California
- +5 more
2022-03-17
Mar 17, 2022